力生制药(002393) - 2017 Q3 - 季度财报

Financial Performance - Operating revenue for the reporting period was CNY 238,159,359.93, representing a year-on-year increase of 33.66%[13] - Net profit attributable to shareholders was CNY 21,616,989.85, a significant increase of 121.86% compared to the same period last year[13] - Basic earnings per share rose to CNY 0.12, reflecting a 140% increase year-on-year[13] - The net profit attributable to shareholders for 2017 is expected to range from 10,404.57 to 13,872.76 million CNY, reflecting a change of -10% to 20% compared to the previous year[18] Assets and Liabilities - Total assets at the end of the reporting period reached CNY 3,576,323,402.48, an increase of 2.60% compared to the end of the previous year[6] - Accounts receivable at the end of the reporting period increased by 37.72% to CNY 89,909,437.35[13] - Prepayments increased by 53.01% to CNY 20,353,714.14, primarily due to increased advance payments for raw material purchases[13] - Other receivables rose by 58.28% to CNY 7,920,079.13, attributed to increased inter-company transactions[13] - As of September 30, 2017, accounts payable decreased by 100% to 0.00 CNY, primarily due to interest payments made by the biopharmaceutical company[5] - Prepayments as of September 30, 2017, amounted to 4,104,725.67 CNY, a decrease of 69.84% compared to the beginning of the period, mainly due to audit adjustments[5] - Other payables increased by 146.29% to 234,731,948.42 CNY as of September 30, 2017, attributed to audit adjustments[5] Cash Flow - Cash flow from operating activities amounted to CNY 96,123,042.55, up by 21.79% from the previous year[6] - Cash paid for purchasing goods and services was 216,378,933.80 CNY, an increase of 66.89% year-on-year, primarily due to increased raw material procurement[5] - Cash received from investment income decreased by 91.16% to 191,421.44 CNY, mainly due to reduced dividends from Tianbian Company[5] - Cash received from financing activities was 35,000,000.00 CNY, an increase of 56.60% year-on-year, primarily due to increased loan receipts by the biopharmaceutical company[20] - Cash paid for fixed assets and other long-term assets was 51,792,496.89 CNY, a decrease of 48.99% year-on-year, primarily due to reduced payments for the new factory project[17] Expenses and Taxes - Management expenses for the first nine months of 2017 totaled 147,978,412.47 CNY, an increase of 56.51% year-on-year, mainly due to increased consistency evaluation costs[5] - The company reported a decrease of 62.40% in taxes payable, amounting to CNY 5,117,678.01 at the end of September[12] - The company reported a 122.94% increase in taxes and additional charges for the first nine months of 2017, totaling 18,672,314.80 CNY, mainly due to reclassification of various taxes[5] - The weighted average return on net assets was 0.69%, up from 0.36% in the previous year[6]